Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia due to chronic kidney disease (CKD). In addition to drug acquisition costs, the administration of ESAs can include direct and indirect costs due to the needle-based route of administration (eg, time spent by healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier-Loiselle, Marjolaine, Michalopoulos, Steven N, Cloutier, Martin, Serra, Elizabeth, Bungay, Rebecca, Szabo, Erika, Guérin, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391171/
https://www.ncbi.nlm.nih.gov/pubmed/34818094
http://dx.doi.org/10.18553/jmcp.2021.27.12.1703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391171/
https://www.ncbi.nlm.nih.gov/pubmed/34818094
http://dx.doi.org/10.18553/jmcp.2021.27.12.1703

Ejemplares similares